| Document |
Document Title |
|
WO/2023/090260A1 |
The purpose of the present invention is to provide a composition for inhibiting histamine-N-methyltransferase. The present invention relates to a composition for inhibiting histamine-N-methyltransferase, said composition including L-ergo...
|
|
WO/2023/090313A1 |
The purpose of the present invention is to newly discover a transient receptor potential ankyrin 1 (TRPA1) agonist that exhibits an action for increasing the amount of food ingested, to provide a novel agonist of TRPA1, or to provide a n...
|
|
WO/2023/090942A1 |
The present invention relates to a pyrrole derivative or a pharmaceutically or sitologically acceptable salt thereof, and a composition for the prevention, amelioration or treatment of gastrointestinal disorders, comprising same as an ac...
|
|
WO/2023/089338A1 |
The present invention provides a clostridial neurotoxin for use in a method of suppressing visceral pain in a patient. The method comprises: (a) identifying an organ in the patient that is causing said visceral pain; (b) mapping said org...
|
|
WO/2023/088425A1 |
Provided are a 15-PGDH inhibitor and the use thereof. The 15-PGDH inhibitor is a heterocyclic compound as represented by formula I, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable...
|
|
WO/2023/092134A1 |
Methods are disclosed herein for promoting survival of a donor liver in a recipient subject, wherein the donor liver is homozygous for rs738409:G mutation in the patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene. The m...
|
|
WO/2023/087944A1 |
Disclosed in the present invention are Pediococcus acidilactici for improving the production performance and immune level of broilers, and a screening method therefor and the use thereof. Provided in the present invention are a new metho...
|
|
WO/2023/090381A1 |
Disclosed is a new anti-HBV agent targeting host factor DOCK11. This anti-HBV agent contains, as an active ingredient, a substance which binds to DOCK11 and inhibits the function of DOCK11. In one embodiment, the anti-HBV according to th...
|
|
WO/2023/088143A1 |
A series of staple-containing polypeptides and an application thereof, and specifically disclosed are polypeptides having sequences as shown in formulas (I-1)-(I-5).
|
|
WO/2023/088086A1 |
The present invention relates to a pair of tissue factors and an application thereof. The tissue factors are respectively TRIM31 and RHBDF2 which are derived from hepatic cells, and the TRIM31 and the RHBDF2 have a trade-off relationship...
|
|
WO/2023/083365A1 |
The present disclosure provides a compound represented by structural formula (I0) or a pharmaceutically acceptable salt, or a stereoisomer thereof and their use in, e.g. treating a disease or disorder associated with the PAD4 activity. T...
|
|
WO/2023/085396A1 |
The present invention relates to providing a pharmaceutical composition that is useful for treating Alport syndrome. The present invention provides a pharmaceutical composition that is useful for treating Alport syndrome and contains a c...
|
|
WO/2023/086620A1 |
The present invention provides compositions and methods for modulating the amount of Akkermansia muciniphila in the gut microbiome of a subject. In a principal embodiment, the invention provides a method of increasing the amount of A. mu...
|
|
WO/2023/082397A1 |
Disclosed are an A-FABP protein inhibitor and a use thereof, relating to the technical field of metabolic diseases, and cardiovascular and cerebrovascular complications thereof. Disclosed is an A-FABP protein inhibitor, an active ingredi...
|
|
WO/2023/084118A1 |
The invention relates to solid composition comprising a peptide or a protein and an acylated aminoacid AC-aa, or a salt thereof, characterized in that: the acyl group -AC comprises from 4 to 9 carbon atoms, said composition comprises at ...
|
|
WO/2023/084488A1 |
A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial intravenous dose and subsequent subcutaneous doses in order for the patient to respond to the antibody and meet one...
|
|
WO/2023/086562A1 |
Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis (NASH), and symptoms and manifestations thereof, in a patient comprising administration of the SSAO inhibitor: or a pharmaceutically accept...
|
|
WO/2023/083983A1 |
The present invention thus provides a novel family of liposomal compositions (nanocarriers), hereinafter referred to as Tetra-Acidosomes, comprising natural tetrameric acid (TA) lipids and/or novel chemically functionalized tetrameric ac...
|
|
WO/2023/086465A1 |
The present disclosure provides LNPs comprising payload molecules, e.g., mRNA therapeutics, for the treatment of diseases or disorders, which would benefit from delivery of payload molecules to airway cells.
|
|
WO/2023/086045A1 |
The invention relates to an irrigation solution that benefits from its antimicrobial activity in root canal treatment and its anti-inflammatory activity in teeth with acute apical periodontitis.
|
|
WO/2023/086561A1 |
Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis (NASH), and symptoms and manifestations thereof, in a patient which utilize, among others, a combination treatment of an SSAO inhibitor and...
|
|
WO/2023/085456A1 |
The present invention relates to a method capable of producing a placenta hydrolysate, the method comprising the steps of: degreasing and drying an animal placenta lysate to obtain animal placenta lysate powder; treating the degreased an...
|
|
WO/2023/081980A1 |
Disclosed are therapeutic compositions comprising bacterial strains and methods for the treatment or prevention of disease. More particularly, the present invention also discloses compositions comprising bacterial strains isolated from t...
|
|
WO/2023/085703A1 |
The present invention provides a composition for curing a hangover or preventing, alleviating or treating alcoholic liver disease, comprising a pine heartwood extract as an active ingredient.
|
|
WO/2023/085894A1 |
The present invention relates to a novel thiourea derivative as an activator of RORα and a pharmaceutical composition comprising same. A compound according to the present invention is expected to be effective in the treatment and preven...
|
|
WO/2023/085440A1 |
Provided is a therapeutic agent or the like that is for refractory viral infections and that is capable of eliminating or decreasing cccDNA in hepatocytes. This therapeutic agent for refractory viral infections according to the present i...
|
|
WO/2023/086910A1 |
Methods of treating Crohn's disease are provided. Also provided are methods of administering and dosing integrin beta7 antagonists, such as anti-integrin beta7 antibodies. In addition, methods of administrating and dosing such integrin b...
|
|
WO/2023/083288A1 |
Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient which utilize treatment with a THR-β agonist.
|
|
WO/2023/086499A1 |
Provided herein are compositions or compounds comprising ionic liquids and therapeutic proteins or peptides, and methods of use thereof for the treatment of diseases or disorders.
|
|
WO/2023/083291A1 |
The present invention relates to compounds of formula I and formula II and the use thereof in the treatment of metabolic diseases such as liver fibrosis and non-alcoholic hepatitis. Specifically, provided are the compounds as shown, and ...
|
|
WO/2023/085415A1 |
Provided is a compound represented by formula (1), or a pharmaceutically acceptable salt thereof. [In the formula, R1 denotes a hydrogen atom, an alkyl group, an alkoxy group or an alkoxyalkyl group, each R2 moiety independently denotes ...
|
|
WO/2023/082218A1 |
A preparation method for nano-selenium sodium alginate composite gel, comprising the following steps: (1) preparing hyaluronic acid modified nano-selenium, adding water into hyaluronic acid, stirring to form a hyaluronic acid solution, a...
|
|
WO/2023/084236A1 |
The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides ...
|
|
WO/2023/085420A1 |
The present invention provides a means whereby it is possible to clarify the mechanism of manifestation of symptoms, an illness, or dysfunction caused by mitochondrial dysfunction and prevent or treat symptoms, an illness, or dysfunction...
|
|
WO/2023/079093A1 |
The present invention relates to polymorphs of the mesylate salt of 5-{2-[({8-[(2,6- dimethylbenzyl)amino]-2,3-dimethylimidazo[l,2-a]pyridine-6-y
l}carbonyl)-amino]ethoxy}-5- oxopentanoic acid (linaprazan glurate), more specifically Form...
|
|
WO/2023/078171A1 |
A Fosaprepitant-containing liquid pharmaceutical composition, a preparation method therefor, and a use thereof. The Fosaprepitant-containing liquid pharmaceutical composition comprises an active pharmaceutical ingredient, a chelating age...
|
|
WO/2023/081893A1 |
Compounds are provided include a cell penetrating peptide, a therapeutic oligonucleotide, and a carbohydrate targeting moiety. The compounds may also include an exocyclic peptide. The compounds may be targeted to liver cells. The therape...
|
|
WO/2023/078220A1 |
An isolated nucleic acid molecule and the use thereof. The nucleic acid molecule comprises a liver-specific expression regulatory element and a target gene, and the liver-specific expression regulatory element can increase the expression...
|
|
WO/2023/078435A1 |
The present invention relates to the technical field of biomedicine. Disclosed is an application of folic acid in prevention, diagnosis, and treatment of hereditary, infectious, or allergic diseases. It is found in the present invention ...
|
|
WO/2023/078378A1 |
A composition containing hyaluronic acids or salts thereof for improving the immunity of an organism and protecting the health of the gastrointestinal tract, and the use thereof. The composition containing hyaluronic acids or salts there...
|
|
WO/2023/081785A1 |
Methods and compositions for assessing the susceptibility of a subject to chemotherapy-induced neuropathy (CIPN) comprising obtaining one or more measurement of the GSH recycling dependent antioxidant activity of the subject's red blood ...
|
|
WO/2023/079520A1 |
An ophthalmic composition comprising a mixture that comprises or, alternatively, consists of: (a) a lubricant agent selected from the group that comprises or, alternatively, consists of (a.1)-(a.14); (b) verbascoside, isoverbascoside or ...
|
|
WO/2023/078821A1 |
In the management of patients with inflammatory bowel diseases (IBD), there is a need to identify druggable biological pathways to improve mucosal repair and efficacy of TNF alpha biologics. Based on the VIVA transgenic model of Vnn1 ove...
|
|
WO/2023/080628A1 |
The present invention provides novel use of apomorphine for the prevention or treatment of necroptosis-related diseases. The present invention relates to a pharmaceutical composition for the prevention or treatment of necroptosis-related...
|
|
WO/2023/079094A1 |
The present invention relates to polymorphs of the hydrochloride salt of 5-{2-[({8-[( 2, 6- dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridine-6-y
l}carbonyl)-amino]ethoxy}-5- oxopentanoic acid (linaprazan glurate), more specifical...
|
|
WO/2023/078426A1 |
Provided in the present invention are a compound, a pharmaceutical composition containing same, and the use thereof. The compound interferes with the interaction between the menin protein and MLL1 or MLL2 or a MLL fusion oncoprotein, and...
|
|
WO/2023/081370A1 |
The present invention relates generally to methods treating cholestatic liver disease by administering an ileal bile acid transporter inhibitor (IBAT inhibitor), wherein the treatment results in increased event-free survival (EPS). The p...
|
|
WO/2023/080460A1 |
The present invention relates to a recombinant protein, recombined on the basis of the milk fat globule-EGF factor 8 (MFG-E8) protein, for preventing or treating ulcerative colitis, wherein the recombinant protein comprises an amino acid...
|
|
WO/2023/081105A1 |
Provided herein are cyclic phosphoramidate compounds, their preparation and their uses, such as treating liver or non-liver diseases or conditions.
|
|
WO/2023/081157A1 |
A method including administering a therapeutically effective amount of a therapeutic agent to a subject for improving exercise performance, treating obesity, fatty liver, rhabdomyolysis, Leigh syndrome, mitochondrial Complex I deficiency...
|
